Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro

被引:0
|
作者
Daisuke Kawasaki
Yutaka Emori
Runa Eta
Yuka Iino
Hiroki Hamano
Koji Yoshinaga
Takao Tanaka
Mineo Takei
Susan A. Watson
机构
[1] Zeria Pharmaceutical Co.,Central Research Laboratories
[2] Ltd,Division of Pre
[3] University of Nottingham,Clinical Oncology
来源
关键词
Z-360; Gastrin; Cholecystokinin (CCK)-2/gastrin receptor; Antagonist; Pancreatic carcinoma; Gemcitabine;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:883 / 892
页数:9
相关论文
共 5 条
  • [1] Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro
    Kawasaki, Daisuke
    Emori, Yutaka
    Eta, Runa
    Iino, Yuka
    Hamano, Hiroki
    Yoshinaga, Koji
    Tanaka, Takao
    Takei, Mineo
    Watson, Susan A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 883 - 892
  • [2] Inhibitory effect of Z-360, a novel, orally active CCK-2/Gastrin receptor antagonist, on gastrin-17-induced proliferation, Pkb/Akt phosphorylation and in vivo growth of human pancreatic adenocarcinoma cell lines
    Emori, Yutaka
    Kawasaki, Daisuke
    Eta, Runa
    Iino, Yuka
    Hamano, Hiroki
    Yoshmaga, Koji
    Tanaka, Takao
    Takei, Mineo
    Watsori, Susan A.
    GASTROENTEROLOGY, 2007, 132 (04) : A433 - A434
  • [3] Pre-clinical characterisation of a novel, high affinity, orally-active CCK-2 receptor antagonist, Z-360, in gastrointestinal malignancy
    Grabowska, Anna M.
    Morris, Teresa M.
    Mckenzie, Andrew J.
    Kumari, Rajendra
    Yoshinaga, Kouji
    Hamano, Hiroki
    Emori, Yutaka
    Watson, Susan A.
    GASTROENTEROLOGY, 2007, 132 (04) : A69 - A69
  • [4] Z-360, a Novel Cholecystokinin-2/Gastrin Receptor Antagonist, Inhibits Gemcitabine-Induced Expression of the Vascular Endothelial Growth Factor Gene in Human Pancreatic Cancer Cells
    Kobayashi, Nobuyoshi
    Seto, Koichi
    Orikawa, Yuki
    Hamano, Hiroki
    Yoshinaga, Koji
    Takei, Mineo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (02) : 216 - 222
  • [5] The effects of the novel, reversible epidermal growth factor Receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo
    Rusnak, DW
    Lackey, K
    Affleck, K
    Wood, ER
    Alligood, KJ
    Rhodes, N
    Keith, BR
    Murray, DM
    Knight, WB
    Mullin, RJ
    Gilmer, TM
    MOLECULAR CANCER THERAPEUTICS, 2001, 1 (02) : 85 - 94